Shanghai Tufeng Pharmaceutical Technology

Shanghai Tufeng Pharmaceutical Technology is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule drugs for cancer treatment. The company utilizes its proprietary fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) platforms to target challenging proteins, particularly those in the RAS signaling pathway. Its lead candidate, TF-001, is a potent and selective SOS1 inhibitor currently undergoing Phase 1 clinical evaluation for KRAS-mutant solid tumors. Headquartered in Shanghai's Zhangjiang Hi-Tech Park, Tufeng is backed by prominent venture capital firms such as Qiming Venture Partners and TF Capital. The company aims to address significant unmet medical needs by providing precision oncology therapies.